Coherus Biosciences (CHRS) PT Lowered to $24 at Credit Suisse; Neulasta Biosimilar CRL Poses Greater Risk for CHS-1701
Tweet Send to a Friend
Credit Suisse lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $24.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
